By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Glenmark Pharmaceuticals 

B/2 & 801-805, Mahalaxmi Chambers
22, Bhulabhai Desai Road
Mumbai    400 026  India
Phone: 91-0-4964893 Fax: 91-0-4932648



Company News
Glenmark Pharma Initiates Clinical Investigation For GBR 310, Its Proposed Biosimilar Candidate For XOLAIR 4/25/2017 8:26:04 AM
Glenmark Pharma Reports Positive Results From A Phase III Trial Of GSP 301, Mometasone/Olopatadine Fixed-Dose Combination Nasal Spray, In Seasonal Allergic Rhinitis 3/29/2017 8:42:49 AM
Glenmark Pharma Receives FDA Clearance Of IND For GSP 304 3/7/2017 9:16:20 AM
Glenmark Pharma And Evestra Announce Partnership Agreement For Generic NuvaRing 3/2/2017 6:58:17 AM
Glenmark Pharma Receives FDA Clearance Of IND For GBR 1302-BEAT Phase I Trial 1/3/2017 6:46:20 AM
Glenmark Pharma' Experimental GBR 1302-BEAT Demonstrates Potent Anti-Tumor Activity In Preclinical Data Presented At The ESMO Symposium On Immuno-Oncology 11/7/2016 8:53:49 AM
Sources Reveal Glenmark Pharma, Sun Pharma (SUNPHARMA.NS), Cipla (CIPLA) are Exploring Bids Worth $500-800 Million for Teva (TEVA)'s Generics Products Portfolio 11/19/2015 6:54:02 AM
Sanofi (SNY) Walks Away from a $613 Million Multiple Sclerosis Pact with Glenmark Pharma 10/30/2015 6:48:43 AM
Jaguar Animal Health Signs Crofelemer Manufacturing & Supply Agreement With Glenmark Pharmaceuticals 9/28/2015 2:07:15 PM
Glenmark Pharmaceuticals's Bi-Specific Antibody - GBR 1302 To Enter Phase I Trials 9/15/2015 5:55:41 AM